Goserelin

Generic Name: Goserelin

Brand Names: Zoladex

Drug Type: Small Molecule

Chemical Formula: C_₅₉H_₈₄N_₁₈O_₁₄

CAS Number: 65807-02-5

Unique Ingredient Identifier: 0F65R8P09N

Background: Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication: Goserelin is indicated for:

Associated Conditions: Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate

Associated Therapies: Palliative Treatment

Clinical Trials

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-04-30

Last Posted Date: 2013-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 18

Registration Number: NCT00003394

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-04-22

Last Posted Date: 2023-08-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 180

Registration Number: NCT00002889

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 9 locations

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-21

Last Posted Date: 2016-03-11

Lead Sponsor: NYU Langone Health

Registration Number: NCT00010010

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States

Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases

Phase 2

Completed

Conditions: Metastatic Cancer
Prostate Cancer

Interventions: Drug: Doxorubicin hydrochloride
Drug: Goserelin acetate
Drug: Leuprolide acetate
Drug: Zoledronic acid
Procedure: orchiectomy
Radiation: strontium chloride Sr

First Posted Date: 2004-04-08

Last Posted Date: 2016-11-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT00081159

Locations: 🇺🇸
M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸
CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States

and more 1 locations

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-03-11

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 1000

Registration Number: NCT00002580

Locations: 🇬🇧
University Hospitals of Leicester, Leicester, England, United Kingdom
🇬🇧
Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom
🇬🇧
Beatson Oncology Centre, Glasgow, Scotland, United Kingdom

and more 7 locations

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Radiation: radiation therapy
Drug: flutamide
Drug: Zoladex
Drug: Lupron

First Posted Date: 2004-02-27

Last Posted Date: 2018-06-14

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 2028

Registration Number: NCT00002597

Locations: 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Wilkes Barre General Hospital, Wilkes-Barre, Pennsylvania, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

and more 236 locations

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: flutamide
Drug: goserelin acetate
Drug: leuprolide acetate
Drug: SU5416
Radiation: radiation therapy

First Posted Date: 2004-02-06

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 3

Registration Number: NCT00026377

Locations: 🇺🇸
Radiation Oncology, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States

Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-11-11

Last Posted Date: 2013-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00012090

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Menopausal Symptoms
Infertility

Interventions: Drug: cyclophosphamide
Drug: goserelin acetate

First Posted Date: 2003-09-11

Last Posted Date: 2019-12-30

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 257

Registration Number: NCT00068601

Locations: 🇦🇺
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
🇦🇺
Royal Hobart Hospital, Hobart, Tasmania, Australia
🇦🇺
Monash Medical Center - Clayton Campus, Clayton, Victoria, Australia

and more 31 locations

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: goserelin acetate
Procedure: assessment of therapy complications
Procedure: quality-of-life assessment
Radiation: radiation therapy

First Posted Date: 2003-08-11

Last Posted Date: 2015-12-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT00067015

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy